News
Tacrolimus in Lupus Nephritis Management
Prof. Sandra Navarra and colleagues compared the efficacy and safety of tacrolimus and glucocorticoids vs. mycophenolate mofetil (MMF) as a continuous induction-maintenance treatment for class III/IV+V lupus nephritis.
ACR 2025 Rheumatology Round Up
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
ACR25 Best Abstracts - Day 4
Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty. Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!
Halloween ACR Guidance (10.31.25)
Dr. Jack Cush recaps ACR2025 with suggestions on how to best learn ACR25 content from RheumNow.com and our articles, videos and podcasts.
Why I love the late breaking abstracts
Every year I love the late breaking abstracts. It’s consistently my favourite part of the meeting program, by some distance. Here's why you should love them, too.
Where are we at with PD-1 agonism?
Promising novel mechanisms of action always create excitement, but the immune checkpoint PD-1 has cemented itself in the news far more than most. This fame is primarily from therapeutic inhibition in cancer and rheumatological inflammatory sequelae that emerge, but invoking the inverse and using PD-1 agonism to treat classical autoimmunity has subsequently been making its own mark. Given the evident plausibility, how do we feel about invoking the opposite and agonising PD-1 in classical autoimmunity?
Bone Density in Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a burden on the bones—both literally and diagnostically. The disease’s dual nature, marked by chronic inflammation and abnormal new bone formation, complicates the assessment of bone health.
IL-23 Blockade Goes Oral
A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies.
Sjogren’s disease: two drugs with positive trials
After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost!
Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA
At ACR Convergence 2025, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in autoimmune disease.
